Please login to the form below

Not currently logged in
Email:
Password:

MSD forms pneumococcal partnership

MSD and Serum Institute of India have formed a partnership to develop a pneumococcal conjugate vaccine

MSD, known as Merck in the US and Canada, and Serum Institute of India are to work together to develop and commercialise a pneumococcal conjugate vaccine (PCV) for use in emerging and developing countries. 

The companies will form a product advisory committee to oversee the activities required to develop and seek approval for PCV and pursue World Health Organisation (WHO) prequalification. 

Under the terms of the agreement, Merck, through an affiliate, will receive specific rights to market PCV in certain designated territories and Serum will receive specific rights in other territories. Both companies will contribute to the development and manufacture of PCV. This collaboration does not impact the ongoing vaccine development programmes in both the organisations.

Julie L Gerberding, president of Merck Vaccines, said: "Working side by side with Serum gives us the best chance of developing and bringing a product to the market that will help to protect more babies and children.

"Expanding vaccine access to emerging and developing markets is a top priority and we feel strongly that this collaboration will be a giant step toward impacting the devastation of pneumococcal disease."

Financial details of the agreement have not been disclosed.

9th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics